GlassScriptPhysician profile
Hunter Lee Lampley
NPI 1033783774
$10,431.18
in general payments reported to CMS, 2019-2025
40 companies · $3,062 in 2025
The $3,062 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $621 · 2022: $2,072 · 2023: $2,253 · 2024: $2,424 · 2025: $3,062.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,614 · Education: $124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,614.10 |
| Education | $124.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,201.71 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,168.19 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $782.71 | 2021-2025 | Xifaxan, Trulance, Plenvu |
| Gilead Sciences, INC. | $562.62 | 2021-2025 | |
| Janssen Biotech, INC. | $536.91 | 2022-2025 | Tremfya, Stelara, Remicade |
| Qol Medical, LLC | $325.51 | 2022-2025 | Sucraid, Sucraid |
| Genzyme Corporation | $318.59 | 2022-2025 | |
| Madrigal Pharmaceuticals | $300.58 | 2025 | Rezdiffra |
| Lilly USA, LLC | $289.00 | 2023-2025 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $276.31 | 2022-2025 | Dupixent |
| Ardelyx, INC. | $229.92 | 2023-2025 | Ibsrela |
| Pfizer INC. | $216.27 | 2021-2025 | |
| Celgene Corporation | $211.40 | 2021-2024 | Zeposia |
| Ironwood Pharmaceuticals, INC | $210.05 | 2021-2024 | Linzess |
| Celltrion USA INC. | $179.66 | 2023-2025 | Vegzelma, Yuflyma |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hunter Lampley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.